Eli Lil­ly re­veals two-year da­ta for ex­per­i­men­tal eczema treat­ment af­ter FDA road­block

Eli Lil­ly is bol­ster­ing the case for its ex­per­i­men­tal eczema treat­ment le­brik­izum­ab with a first look at how pa­tients fared af­ter two years of main­te­nance treat­ment.

Al­most 80% of mod­er­ate-to-se­vere atopic der­mati­tis pa­tients on once-month­ly le­brik­izum­ab main­tained clear or al­most clear skin at two years, Lil­ly an­nounced on Fri­day. The safe­ty pro­file was al­so “con­sis­tent with pre­vi­ous le­brik­izum­ab stud­ies in pa­tients with mod­er­ate-to-se­vere atopic der­mati­tis” with no new sig­nals seen, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER